Anthrax lethal factor is a MAPK kinase protease
US6485925B1 · kind B1 · utility
8Cited by
3References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 13, 2000 |
| Grant date | Nov 26, 2002 |
| Priority date | — |
| Expiry date | Dec 13, 2020 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2500/00
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present invention relates to in vitro and ex vivo methods of screening for modulators, homologues, and mimetics of lethal factor mitogen activated protein kinase kinase (MAPKK) protease activity, as well as methods of treating cancer by administering LF to transformed cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.